Log In
BCIQ
Print this Print this
 

VAL401

  Manage Alerts
Collapse Summary General Information
Company ValiRx plc
DescriptionOral reformulation of an undisclosed marketed drug approved for a non-cancer indication
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationLung cancer
Indication DetailsTreat lung cancer; Treat non-small cell lung cancer (NSCLC)
Regulatory Designation
PartnerSeek Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$0.1M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/14/2014

Undisclosed

$0.1M

Undisclosed

Get a free BioCentury trial today